Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modified polynucleotides encoding cd28 molecule

a technology of cd28 and polynucleotides, which is applied in the direction of peptide/protein ingredients, dna/rna fragmentation, peptide delivery, etc., can solve the problems of affecting the dna expression of host cells, and each step represents an opportunity for error and damage to the cell, and is known to be difficult to obtain dna expression in cells

Inactive Publication Date: 2014-06-19
MODERNA THERAPEUTICS INC
View PDF0 Cites 110 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are multiple problems with prior methodologies of effecting protein expression.
For example, introduced DNA can integrate into host cell genomic DNA at some frequency, resulting in alterations and / or damage to the host cell genomic DNA.
Not only do the multiple processing steps from administered DNA to protein create lag times before the generation of the functional protein, each step represents an opportunity for error and damage to the cell.
Further, it is known to be difficult to obtain DNA expression in cells as DNA frequently enters a cell but is not expressed or not expressed at reasonable rates or concentrations.
This can be a particular problem when DNA is introduced into primary cells or modified cell lines.
However, the low levels of translation and the immunogenicity of the molecules hampered the development of mRNA as a therapeutic and efforts have since focused on alternative applications that could instead exploit these pitfalls, i.e. immunization with mRNAs coding for cancer antigens.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified polynucleotides encoding cd28 molecule
  • Modified polynucleotides encoding cd28 molecule
  • Modified polynucleotides encoding cd28 molecule

Examples

Experimental program
Comparison scheme
Effect test

example 1

Modified mRNA Production

[1140]Modified mRNAs (mmRNA) according to the invention may be made using standard laboratory methods and materials. The open reading frame (ORF) of the gene of interest may be flanked by a 5′ untranslated region (UTR) which may contain a strong Kozak translational initiation signal and / or an alpha-globin 3′ UTR which may include an oligo(dT) sequence for templated addition of a poly-A tail. The modified mRNAs may be modified to reduce the cellular innate immune response. The modifications to reduce the cellular response may include pseudouridine (ψ) and 5-methyl-cytidine (5meC, 5mc or m5C). (See, Kariko K et al. Immunity 23:165-75 (2005), Kariko K et al. Mol Ther 16:1833-40 (2008), Anderson B R et al. NAR (2010); each of which are herein incorporated by reference in their entireties).

[1141]The ORF may also include various upstream or downstream additions (such as, but not limited to, β-globin, tags, etc.) may be ordered from an optimization service such as, ...

example 2

PCR for cDNA Production

[1158]PCR procedures for the preparation of cDNA are performed using 2×KAPA HIFI™ HotStart ReadyMix by Kapa Biosystems (Woburn, Mass.). This system includes 2×KAPA ReadyMix12.5 μl; Forward Primer (10 uM) 0.75 μl; Reverse Primer (10 uM) 0.75 μl; Template cDNA 100 ng; and dH20 diluted to 25.0 μl. The reaction conditions are at 95° C. for 5 min. and 25 cycles of 98° C. for 20 sec, then 58° C. for 15 sec, then 72° C. for 45 sec, then 72° C. for 5 min. then 4° C. to termination.

[1159]The reverse primer of the instant invention incorporates a poly-T120 for a poly-A120 in the mRNA. Other reverse primers with longer or shorter poly(T) tracts can be used to adjust the length of the poly(A) tail in the mRNA.

[1160]The reaction is cleaned up using Invitrogen's PURELINK™ PCR Micro Kit (Carlsbad, Calif.) per manufacturer's instructions (up to 5 μg). Larger reactions will require a cleanup using a product with a larger capacity. Following the cleanup, the cDNA is quantified ...

example 3

In Vitro Transcription (IVT)

[1161]The in vitro transcription reaction generates mRNA containing modified nucleotides or modified RNA. The input nucleotide triphosphate (NTP) mix is made in-house using natural and un-natural NTPs.

[1162]A typical in vitro transcription reaction includes the following:

1Template cDNA1.0μg210x transcription buffer (400 mM Tris-2.0μlHCl pH 8.0, 190 mM MgCl2, 50 mM DTT,10 mM Spermidine)3Custom NTPs (25 mM each)7.2μl4RNase Inhibitor20U5T7 RNA polymerase3000U6dH20Up to 20.0 μl. and7Incubation at 37° C. for 3 hr-5 hrs.

[1163]The crude IVT mix may be stored at 4° C. overnight for cleanup the next day. 1 U of RNase-free DNase is then used to digest the original template. After 15 minutes of incubation at 37° C., the mRNA is purified using Ambion's MEGACLEAR™ Kit (Austin, Tex.) following the manufacturer's instructions. This kit can purify up to 500 μg of RNA. Following the cleanup, the RNA is quantified using the NanoDrop and analyzed by agarose gel electrophore...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
compositionsaaaaaaaaaa
Login to View More

Abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 13 / 791,910, filed Mar. 9, 2013, entitled Modified Polynucleotides for the Production of Proteins Associated with Human Disease which claims priority to U.S. Provisional Patent Application No. 61 / 681,742, filed, Aug. 10, 2012, entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides, U.S. Provisional Patent Application No. 61 / 737,224, filed Dec. 14, 2012, entitled Terminally Optimized Modified RNAs, International Application No PCT / US2012 / 069610, filed Dec. 14, 2012, entitled Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions, U.S. Provisional Patent Application No. 61 / 618,862, filed Apr. 2, 2012, entitled Modified Polynucleotides for the Production of Biologics, U.S. Provisional Patent Application No. 61 / 681,645, filed Aug. 10, 2012, entitled Modified Polynucleotides for the Production of Biologics, U.S. Provisional Pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/87C12P13/04
CPCC12N15/87C12P13/04C12Y603/02019C12N15/85C12N9/93A61K38/45A61K38/17C07H21/02C12N9/0069C12N9/0091C12N9/1241C12N9/6435C12N9/6437C12N9/644C12N9/6443C12Y113/12007C12Y116/03001C12Y207/07012C12Y304/21007C12Y304/21022C12Y304/21027C12Y403/02001A61K48/005A61K38/1816A61K38/1891A61K38/191A61K38/193A61K38/212A61K38/4846A61P1/00A61P1/04A61P11/00A61P13/00A61P13/12A61P15/00A61P17/00A61P17/02A61P17/04A61P17/06A61P17/08A61P17/14A61P19/00A61P19/02A61P19/10A61P21/00A61P21/04A61P25/00A61P25/02A61P25/14A61P25/18A61P25/24A61P25/28A61P25/30A61P27/02A61P29/00A61P3/00A61P31/00A61P31/04A61P31/10A61P31/12A61P31/14A61P31/18A61P35/00A61P35/02A61P3/06A61P35/04A61P37/00A61P37/02A61P37/06A61P37/08A61P43/00A61P5/00A61P7/00A61P7/02A61P7/04A61P7/06A61P9/00A61P9/10A61P3/10Y02A50/30C12N15/88A61K48/0041A61K9/0019A61K9/5123C07K14/4713C07K14/62A61K31/7115C07K14/47C12N9/88A61K38/00A61K9/1271A61K48/0066C12N15/11C07K14/705C07K14/505C07K14/535C12N9/6451C12N9/1051C12N9/2445C07K14/4705C07K14/005C12N9/16C12N9/2402C12N15/52A61K38/177C07K14/435C12P21/00A61K48/0033C07K14/485C07K14/43595C07K14/4723C07K14/4746C07K14/475C07K14/495C07K14/525C07K14/5418C07K14/56C07K14/61C07K14/745C07K16/2863C07K16/2887C07K16/40A61K47/543A61K9/145A61K9/5146A61K9/5153A61K48/0075C07K14/515C07K16/00C12P21/005
Inventor BANCEL, STEPHANECHAKRABORTY, TIRTHADE FOUGEROLLES, ANTONINWHORISKEY, SUSANWEISS, RON
Owner MODERNA THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com